Table 2:
Open in new tab

Efficacy rates of the three groups during each follow-up period.

GroupEfficacy4 weeks8 weeks12 weeks16 weeks20 weeks24 weeks
Whole telitacicept group (n = 42)Effective, n (%)13 (30.95)19 (45.24)24 (66.67)16 (66.67)13 (76.47)7 (77.78)
Ineffective, n (%)29 (69.05)23 (54.76)12 (33.33)8 (33.33)4 (23.53)2 (22.22)
Total, n42423624179
Newly treated telitacicept subgroup (n = 20)Effective, n (%)8 (40)11 (55.00)16 (84.21)14 (87.50)11 (91.67)7 (100.00)
Ineffective, n (%)12 (60)9 (45.00)3 (15.79)2 (12.50)1 (8.33)0 (0.00)
Total, n20201916127
Conventional IS group (n = 28)Effective, n (%)8 (28.57)14 (50.00)20 (71.43)20 (71.43)17 (68.00)14 (77.78)
Ineffective, n (%)20 (71.43)14 (50.00)8 (28.57)8 (28.57)8 (32.00)4 (22.22)
Total, n282828282518
P-value.685.765.382.325.303.503
GroupEfficacy4 weeks8 weeks12 weeks16 weeks20 weeks24 weeks
Whole telitacicept group (n = 42)Effective, n (%)13 (30.95)19 (45.24)24 (66.67)16 (66.67)13 (76.47)7 (77.78)
Ineffective, n (%)29 (69.05)23 (54.76)12 (33.33)8 (33.33)4 (23.53)2 (22.22)
Total, n42423624179
Newly treated telitacicept subgroup (n = 20)Effective, n (%)8 (40)11 (55.00)16 (84.21)14 (87.50)11 (91.67)7 (100.00)
Ineffective, n (%)12 (60)9 (45.00)3 (15.79)2 (12.50)1 (8.33)0 (0.00)
Total, n20201916127
Conventional IS group (n = 28)Effective, n (%)8 (28.57)14 (50.00)20 (71.43)20 (71.43)17 (68.00)14 (77.78)
Ineffective, n (%)20 (71.43)14 (50.00)8 (28.57)8 (28.57)8 (32.00)4 (22.22)
Total, n282828282518
P-value.685.765.382.325.303.503
Table 2:
Open in new tab

Efficacy rates of the three groups during each follow-up period.

GroupEfficacy4 weeks8 weeks12 weeks16 weeks20 weeks24 weeks
Whole telitacicept group (n = 42)Effective, n (%)13 (30.95)19 (45.24)24 (66.67)16 (66.67)13 (76.47)7 (77.78)
Ineffective, n (%)29 (69.05)23 (54.76)12 (33.33)8 (33.33)4 (23.53)2 (22.22)
Total, n42423624179
Newly treated telitacicept subgroup (n = 20)Effective, n (%)8 (40)11 (55.00)16 (84.21)14 (87.50)11 (91.67)7 (100.00)
Ineffective, n (%)12 (60)9 (45.00)3 (15.79)2 (12.50)1 (8.33)0 (0.00)
Total, n20201916127
Conventional IS group (n = 28)Effective, n (%)8 (28.57)14 (50.00)20 (71.43)20 (71.43)17 (68.00)14 (77.78)
Ineffective, n (%)20 (71.43)14 (50.00)8 (28.57)8 (28.57)8 (32.00)4 (22.22)
Total, n282828282518
P-value.685.765.382.325.303.503
GroupEfficacy4 weeks8 weeks12 weeks16 weeks20 weeks24 weeks
Whole telitacicept group (n = 42)Effective, n (%)13 (30.95)19 (45.24)24 (66.67)16 (66.67)13 (76.47)7 (77.78)
Ineffective, n (%)29 (69.05)23 (54.76)12 (33.33)8 (33.33)4 (23.53)2 (22.22)
Total, n42423624179
Newly treated telitacicept subgroup (n = 20)Effective, n (%)8 (40)11 (55.00)16 (84.21)14 (87.50)11 (91.67)7 (100.00)
Ineffective, n (%)12 (60)9 (45.00)3 (15.79)2 (12.50)1 (8.33)0 (0.00)
Total, n20201916127
Conventional IS group (n = 28)Effective, n (%)8 (28.57)14 (50.00)20 (71.43)20 (71.43)17 (68.00)14 (77.78)
Ineffective, n (%)20 (71.43)14 (50.00)8 (28.57)8 (28.57)8 (32.00)4 (22.22)
Total, n282828282518
P-value.685.765.382.325.303.503
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close